PAR 8.00% 23.0¢ paradigm biopharmaceuticals limited..

research reports and media, page-744

  1. 8,392 Posts.
    lightbulb Created with Sketch. 257
    There will always be competition in this space..... Any business case/ market share and/or revenue estimates by necessity have to be conservative and should never assume complete domination of the market imo
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.